Lower-dose protocols may allow patients not seeking significant weight loss to explore the broad range of health benefits of GLP-1s while aiming to reduce side effects, preserve muscle, and keep treatment aligned with their long-term health goals
Still, with up to one million Americans affected by Parkinsons, these results are highly encouraging, and the results of a larger phase 3 trial testing another GLP-1 agonist (exenatide) as a Parkinsons treatment are expected in 2024
Nat Commun 16 , 7459 (2025)
GLP-1 medications have seen tailwinds in recent times with most pharmaceutical businesses
Some psychiatric medications, particularly certain antidepressants and antipsychotics, are associated with weight gain
RM: Data curation, Writing review and editing